188Re-HEDP therapy in the therapy of painful bone metastases

188Re-HEDP therapy in the therapy of painful bone metastases

For bone-targeted radionuclide therapy (BTRT), different commercial radiopharmaceuticals are available such as strontium-89, 186Rhenium-hydroxyethylidene diphosphonate (186Re-HEDP), Samarium-153-ethylenediamine tetramethylene phosphonic acid, and radium-223. Unfortunately, the commercial available r...

Full description

Bibliographic Details
Main Author: Knut Liepe
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Bone metastases
bone-targeted radionuclide therapy
breast cancer
pain
prostate cancer
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=3;spage=133;epage=138;aulast=Liepe

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=3;spage=133;epage=138;aulast=Liepe

Similar Items